Virus-Tumor Interactome Screen Reveals ER Stress Response Can Reprogram Resistant Cancers for Oncolytic Virus-Triggered Caspase-2 Cell Death

Cancer Cell

Volumn 20, Issue 4, 2011, Pages 443-456

  Mahoney, Douglas J ^a,b   Lefebvre, Charles ^a,b   Allan, Kristina ^a   Brun, Jan ^a,b   Sanaei, Cina A ^a   Baird, Stephen ^a,b   Pearce, Nelson ^a   Grönberg, Susanna ^a   Wilson, Brian ^d   Prakesh, Mikael ^d   Aman, Ahmed ^d   Isaac, Methvin ^d   Mamai, Ahmed ^d   Uehling, David ^d   Al Awar, Rima ^d   Falls, Theresa ^c   Alain, Tommy ^e   Stojdl, David F ^a,b  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 2; ONCOLYTIC VIRUS; PROTEIN IRE1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; ENDOPLASMIC RETICULUM STRESS; FEMALE; GENETIC SCREENING; GENOMICS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; RHABDOVIRUS; RHABDOVIRUS INFECTION; RNA INTERFERENCE;

RHABDOVIRIDAE;

EID: 80054764086     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2011.09.005     Document Type: Article

References (33)

1. Balachandran S., Barber G.N. Vesicular stomatitis virus (VSV) therapy of tumors. IUBMB Life 2000, 50:135-138.
2. Black B.L., Lyles D.S. Vesicular stomatitis virus matrix protein inhibits host cell-directed transcription of target genes in vivo. J. Virol. 1992, 66:4058-4064.
3. Boettcher M., Kischkel F., Hoheisel J.D. High-definition DNA methylation profiles from breast and ovarian carcinoma cell lines with differing doxorubicin resistance. PLoS One 2010, 5:e11002.
4. Bouchier-Hayes L., Oberst A., McStay G.P., Connell S., Tait S.W., Dillon C.P., Flanagan J.M., Beere H.M., Green D.R. Characterization of cytoplasmic caspase-2 activation by induced proximity. Mol. Cell 2009, 35:830-840.
5. Breitbach C.J., Paterson J.M., Lemay C.G., Falls T.J., McGuire A., Parato K.A., Stojdl D.F., Daneshmand M., Speth K., Kirn D., et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol. Ther. 2007, 15:1686-1693.
6. Brun J., McManus D., Lefebvre C., Hu K., Falls T., Atkins H., Bell J.C., McCart J.A., Mahoney D., Stojdl D.F. Identification of genetically modified Maraba virus as an oncolytic rhabdovirus. Mol. Ther. 2010, 18:1440-1449.
7. Cheung H.H., Lynn Kelly N., Liston P., Korneluk R.G. Involvement of caspase-2 and caspase-9 in endoplasmic reticulum stress-induced apoptosis: a role for the IAPs. Exp. Cell Res. 2006, 312:2347-2357.
8. Chou T.C., Motzer R.J., Tong Y., Bosl G.J. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J. Natl. Cancer Inst. 1994, 86:1517-1524.
9. Chung N., Zhang X.D., Kreamer A., Locco L., Kuan P.F., Bartz S., Linsley P.S., Ferrer M., Strulovici B. Median absolute deviation to improve hit selection for genome-scale RNAi screens. J. Biomol. Screen. 2008, 13:149-158.
10. Glimcher L.H. XBP1: the last two decades. Ann. Rheum. Dis. 2010, 69(Suppl 1):i67-i71.
11. Hamilton T.C., Young R.C., McKoy W.M., Grotzinger K.R., Green J.A., Chu E.W., Whang-Peng J., Rogan A.M., Green W.R., Ozols R.F. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 1983, 43:5379-5389.
12. Hetz C. The UPR as a survival factor of cancer cells: more than folding proteins?. Leuk. Res. 2009, 33:880-882.
13. Kaufman H.L., Bines S.D. OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol. 2010, 6:941-949.
14. Lal R., Harris D., Postel-Vinay S., de Bono J. Reovirus: rationale and clinical trial update. Curr. Opin. Mol. Ther. 2009, 11:532-539.
15. Liu J., HuangFu W.C., Kumar K.G., Qian J., Casey J.P., Hamanaka R.B., Grigoriadou C., Aldabe R., Diehl J.A., Fuchs S.Y. Virus-induced unfolded protein response attenuates antiviral defenses via phosphorylation-dependent degradation of the type I interferon receptor. Cell Host Microbe 2009, 5:72-83.
16. Louie K.G., Behrens B.C., Kinsella T.J., Hamilton T.C., Grotzinger K.R., McKoy W.M., Winker M.A., Ozols R.F. Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res. 1985, 45:2110-2115.
17. IRE-1alpha inhibitors. World Intellectual Property Organization WO 2008, 2008/154484:A1. Mannkind-Corporation.
18. Manzl C., Krumschnabel G., Bock F., Sohm B., Labi V., Baumgartner F., Logette E., Tschopp J., Villunger A. Caspase-2 activation in the absence of PIDDosome formation. J. Cell Biol. 2009, 185:291-303.
19. Moenner M., Pluquet O., Bouchecareilh M., Chevet E. Integrated endoplasmic reticulum stress responses in cancer. Cancer Res. 2007, 67:10631-10634.
20. Müller U., Steinhoff U., Reis L.F., Hemmi S., Pavlovic J., Zinkernagel R.M., Aguet M. Functional role of type I and type II interferons in antiviral defense. Science 1994, 264:1918-1921.
21. Ottolino-Perry K., Diallo J.S., Lichty B.D., Bell J.C., McCart J.A. Intelligent design: combination therapy with oncolytic viruses. Mol. Ther. 2010, 18:251-263.
22. Parato K.A., Lichty B.D., Bell J.C. Diplomatic immunity: turning a foe into an ally. Curr. Opin. Mol. Ther. 2009, 11:13-21.
23. Sinkovics J.G., Horvath J.C. Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers. Arch. Immunol. Ther. Exp. (Warsz.) 2008, 56(Suppl 1):3s-59s.
24. Stojdl D.F., Abraham N., Knowles S., Marius R., Brasey A., Lichty B.D., Brown E.G., Sonenberg N., Bell J.C. The murine double-stranded RNA-dependent protein kinase PKR is required for resistance to vesicular stomatitis virus. J. Virol. 2000, 74:9580-9585.
25. Stojdl D.F., Lichty B., Knowles S., Marius R., Atkins H., Sonenberg N., Bell J.C. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 2000, 6:821-825.
26. Stojdl D.F., Lichty B.D., tenOever B.R., Paterson J.M., Power A.T., Knowles S., Marius R., Reynard J., Poliquin L., Atkins H., et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003, 4:263-275.
27. Tinel A., Tschopp J. The PIDDosome, a protein complex implicated in activation of caspase-2 in response to genotoxic stress. Science 2004, 304:843-846.
28. Todd D.J., Lee A.H., Glimcher L.H. The endoplasmic reticulum stress response in immunity and autoimmunity. Nat. Rev. Immunol. 2008, 8:663-674.
29. Vähä-Koskela M.J., Heikkilä J.E., Hinkkanen A.E. Oncolytic viruses in cancer therapy. Cancer Lett. 2007, 254:178-216.
30. Vakifahmetoglu-Norberg H., Zhivotovsky B. The unpredictable caspase-2: what can it do?. Trends Cell Biol. 2010, 20:150-159.
31. Vembar S.S., Brodsky J.L. One step at a time: endoplasmic reticulum-associated degradation. Nat. Rev. Mol. Cell Biol. 2008, 9:944-957.
32. Volkmann K., Lucas J.L., Vuga D., Wang X., Brumm D., Stiles C., Kriebel D., Der-Sarkissian A., Krishnan K., Schweitzer C., et al. Potent and selective inhibitors of the inositol-requiring enzyme 1 endoribonuclease. J. Biol. Chem. 2011, 286:12743-12755.
33. Wang Q., Mora-Jensen H., Weniger M.A., Perez-Galan P., Wolford C., Hai T., Ron D., Chen W., Trenkle W., Wiestner A., Ye Y. ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. Proc. Natl. Acad. Sci. USA 2009, 106:2200-2205.